Chengdu Kanghong Pharmaceutical Group Co., Ltd. (002773.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 19.24

From 52W high−48.90%

Volume5.68M

Market capCNY 18.87B

P/E (TTM)16.2x

P/S (TTM)4.1x

Div yield3.58%

Key dataSep 18, 2026

Open

CNY 19.24

From 52W high

−48.90%

Volume

5.68M

Market cap

CNY 18.87B

ValuationView details →

P/E (Fwd)

24.4x

EV/EBITDA

7.2x

P/E (TTM)

16.2x

RSI (14)

38.6

MomentumView details →

1D Return

−2.98%

YTD Return

−34.77%

ValuationView details →

P/E (Fwd)

24.4x

P/E (TTM)

16.2x

EV/EBITDA

7.2x

EV/Sales

2.6x

P/S (TTM)

4.1x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

89.65%

Net Margin

24.15%

EBITDA Margin

36.53%

ROE (TTM)

11.14%

ROA (TTM)

10.48%

Asset Turnover

0.44x

GrowthView details →

Revenue YoY

−2.76%

EPS YoY

−12.32%

FCF YoY

−12.01%

Revenue CAGR 3Y

+10.60%

EPS CAGR 3Y

+8.74%

EBITDA YoY

—

MomentumView details →

1D Return

−2.98%

YTD Return

−34.77%

1Y Return

−47.16%

RSI (14)

38.6

vs 50D SMA

−8.12%

vs 200D SMA

−23.37%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

12.70x

Quick Ratio

11.99x

Div Yield

3.58%

Div Rate

CNY 0.70

Div Growth 1Y

+16.67%

EarningsView details →

EPS (Actual)

CNY 0.28

EPS Surprise

833.33%

Beats (12Q)

1/12

Next Q EPS Est

CNY 0.19

Avg Surprise (4Q)

833.33%

Rev Surprise

44.68%

Financials snapshotView financials →

Revenue (TTM)

4.43B

Net Income (TTM)

1.07B

Op. CF (TTM)

1.41B

Next earningsOct 23, 2026 →

Latest newsMore news →

Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.17d ago

Kanghong Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 565 million yuan, down 22.61% year-on-year.26d ago

Similar companies

大博医疗002901.SZ 东田微301183.SZ 鸿日达301285.SZ 珠江啤酒002461.SZ 鞍钢股份000898.SZ 唯特偶301319.SZ Find similar companies →

Latest newsMore news →

Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.17d ago Kanghong Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 565 million yuan, down 22.61% year-on-year.26d ago